Immutep - Half Yearly Report and Accounts (ASX:IMM) 23 Feb, 2022 06:22 PM To view the report, download the attached PDF.
Immutep to present new data from TACTI-002 at ELCC 2022 (ASX:IMM) 18 Feb, 2022 08:13 AM SYDNEY, AUSTRALIA – 18 February 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be pre...read more
Immutep Investor Update (ASX:IMM) 18 Feb, 2022 08:11 AM I hope that this newsletter finds you and your families safe and well. I am pleased to report that the Immutep team is helping to lead the LAG-3 therapeutic space as we advance the development of...read more
Immutep - Australian Patent Granted for Efti with PD-1 Inhibitors (ASX:IMM) 11 Feb, 2022 11:58 AM Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmun...read more
Immutep - Change in substantial holding (ASX:IMM) 02 Feb, 2022 08:25 AM To view the Notice of change of interests of substantial holder, download the attached PDF.
